ST. PAUL, Minn. , Nov. 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Stifel Healthcare Conference on Wednesday, Nov. 12, 2025 , beginning at approximately 11:20 a.m. EST in New York, NY . A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com . About Solventum At Solventum, we enable... Read More

ST. PAUL, Minn. , Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025 . In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson . Ms. Knight brings over 30... Read More

ST. PAUL, Minn. , Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025 , after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date:... Read More

ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes"). The Tender Offers are being made pursuant to the terms... Read More

ST. PAUL, Minn. , Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap"). Solventum has... Read More

Accelerates Solventum's business transformation to deliver long-term shareholder value Net proceeds will be used primarily to pay down debt ST. PAUL, Minn. , Sept. 2, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced it has completed the sale of its Purification & Filtration business ("P&F") to Thermo Fisher Scientific Inc. (NYSE: TMO) (" Thermo Fisher ") for $4.0 billion in cash before customary adjustments.... Read More

ST. PAUL, Minn. , Aug. 28, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that management will participate in fireside chats at the following investor conferences: 2025 Wells Fargo Healthcare Conference in Boston, Mass. , on Friday, Sept. 5, 2025 , at 10:15 a.m. EDT . Morgan Stanley 23 rd Annual Global Healthcare Conference in New York, N.Y. , on Tuesday, Sept. 9, 2025 , at 10:45 a.m. EDT . Live and archived... Read More

ST. PAUL, Minn. , Aug. 22, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) announced today that it has commenced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for up to $1.75 billion aggregate purchase price in cash (the "Aggregate Cap"). The Tender Offers are being made pursuant to the terms... Read More

ST. PAUL, Minn. , Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder"). All of the shares of common stock are being sold by the... Read More

Reported sales increased 3.9%; organic sales increased 2.8% Increases full year organic sales growth outlook to +2.0% to +3.0% Increases full year earnings per share outlook to $5.80 to $5.95 ST. PAUL, Minn. , Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the second quarter ended June 30, 2025 . Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion ; up 2.8% on an... Read More

ST. PAUL, Minn. , July 17, 2025 /PRNewswire/ - - Solventum (NYSE: SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025 , after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date:... Read More

Recognized among the top 25 percent of companies in healthcare and research, and top 25 percent of companies in the Midwest in just 14 months as a new company Award highlights success in phase one of Solventum's three-phased Transformation Plan ST. PAUL, Minn. , June 18, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV), a global leader in innovative medical technology and solutions, today announced U.S. News & World Report has... Read More

ST. PAUL, Minn. , June 3, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the Goldman Sachs 46 th Annual Global Health Care Conference on Tuesday, June 10, 2025 , beginning at approximately 4:00 p.m. EDT in Miami, FL. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com . About Solventum At... Read More

ST. PAUL, Minn. , May 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025 , beginning at approximately 2:20 p.m. PST in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com . About Solventum At Solventum, we... Read More

Reported sales increased 2.6%; organic sales increased 4.3% Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5% ST. PAUL, Minn. , May 8, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the first quarter ended March 31, 2025 . First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion ; up 4.3% on an organic basis GAAP diluted earnings per share of $0.78 ;... Read More

ST. PAUL, Minn. , April 17, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025 , after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date:... Read More

In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental offerings, reaffirming its commitment to solving industry's toughest problems Partnership aims to integrate innovative new material science and disruptive technology like chairside 3D printing to optimize workflows, enhance... Read More

Provides 2028 Targets for Revenue Growth, Margin Expansion, and Free Cash Flow ST. PAUL, Minn. , March 20, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today hosts its 2025 Investor Day and will outline strategic priorities for the Company, its business segments, and its long-range plan (LRP) to drive growth and value creation. "Solventum has tremendous potential, with attractive businesses, large and growing markets, and... Read More

ST. PAUL, Minn. , March 12, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV), formerly 3M Health Care, today announced the launch of the Attest™ eBowie-Dick Test System (eBowie-Dick System), an electronic test card and auto-reader for sterilization testing that eliminates the need for visual interpretation of results and manual... Read More

Reported sales increased 1.9% to $2.074 billion ; organic sales increased 2.3% GAAP diluted Earnings Per Share (EPS) of $0.17 ; adjusted EPS 1 of $1.41 Generated $219 million in cash from operations; free cash flow of $92 million Introduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn. , Feb. 27, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for... Read More

Learn more about Solventum's long-term strategy to accelerate growth Join in person or via virtual webcast ST. PAUL, Minn. , Feb. 26, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will host an investor day on Thursday, March 20, 2025 , beginning at approximately 1:00 p.m. Eastern Standard Time . The event will be held in New York City and simultaneously webcast online. More information about this event, including registration... Read More

Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder value Strengthens balance sheet with proceeds to be used primarily for debt paydown ST. PAUL, Minn. , Feb. 25, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration 1 business to Thermo Fisher Scientific Inc.... Read More

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in... Read More

ST. PAUL, Minn. , Feb. 5, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) Solventum today announced that its AI-powered radiology speech reporting solution, Solventum™ Fluency™ for Imaging, has ranked #1 in the 2025 Best in KLAS Awards—Software and Services Report for the fifth time. Enabling faster, more accurate documentation, Solventum Fluency for Imaging helps radiologists save time, reduce burnout and improve efficiency by... Read More

Company to host an Investor Day in March 2025 ST. PAUL, Minn. , Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025 , after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may... Read More

Despite Performance Declines Since Spinning Out of 3M, Trian Believes Solventum Has Potential to Drive Significant Improvements as a Standalone Company If Solventum Can Restore Performance to Historical Levels, Trian Believes the Company’s Shares Could be Worth $140 by Year-End 2027 vs. its $69 Share Price Today Trian Believes the Company Can Further Enhance Value Creation Through Improved Operating Performance, Portfolio... Read More

Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and... Read More

ST. PAUL, Minn. , Nov. 19, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that its executives will participate in a fireside chat at the Piper Sandler 36 th Annual Healthcare Conference on Wednesday, December 4, 2024 at 11:30 a.m. ET in New York, NY . A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com . About Solventum At Solventum, we enable... Read More

Clarity Precision Grip Attachments are fully cured, pre-loaded and precisely resemble the digital treatment plan after bonding ST. PAUL, Minn. , Nov. 14, 2024 /PRNewswire/ -- This month, Solventum (NYSE: SOLV), formerly 3M Health Care, officially launched an anticipated innovation in aligner treatment, 3M™ Clarity™ Precision Grip Attachments . Available exclusively with 3M™ Clarity™ Aligners, Clarity Precision Grip... Read More

Reported sales increased 0.4% to $2.082 billion ; organic sales increased 0.3% GAAP Earnings Per Share (EPS) of $0.70 ; adjusted EPS 1 of $1.64 Generated $169 million in cash from operations; free cash flow 1 of $76 million Raises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidance ST. PAUL, Minn. , Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third... Read More